Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.44 |
| ▸ | CALCR | P30988 | 3/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29629087 | 0.94 | MAPK8 (0.46) | CXCR4MAPK8MAPK9MAPK10IL23R | |
| SCHEMBL24485881 | 0.94 | MAPK8 (0.46) | CXCR4MAPK8MAPK9MAPK10IL23R | |
| SCHEMBL16351201 | 0.91 | GRB2 (0.47) | GRB2CAPN1 | |
| SCHEMBL31188444 | 0.89 | NRP1 (0.48) | OPRM1OPRK1RAMP3CALCR | |
| SCHEMBL24485493 | 0.89 | F2 (0.49) | CXCR4GRB2OPRM1OPRK1 | |
| SCHEMBL30811217 | 0.88 | OPRM1 (0.48) | CXCR4GRB2OPRM1OPRK1 | |
| SCHEMBL16351063 | 0.88 | GRB2 (0.47) | CXCR4MAPK8MAPK9MAPK10GRB2 | |
| SCHEMBL11170810 | 0.88 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL11168724 | 0.88 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 | |
| SCHEMBL9764520 | 0.88 | RAMP3 (0.48) | MAPK8MAPK9MAPK10OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-7884183-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2011-02-08 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820621-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2010-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | CXCR4 25/4885MAPK8 4084/4885MAPK9 3989/4885 |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | CXCR4 25/4885MAPK8 4084/4885MAPK9 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.